300404 博济医药
已收盘 12-05 15:00:00
资讯
新帖
简况
博济医药：12月3日高管王廷春减持股份合计240.91万股
证券之星 · 12-04 21:02
博济医药：12月3日高管王廷春减持股份合计240.91万股
博济医药：12月1日高管王廷春减持股份合计48万股
证券之星 · 12-02
博济医药：12月1日高管王廷春减持股份合计48万股
12月1日博济医药现690.4万元大宗交易
证券之星 · 12-01
12月1日博济医药现690.4万元大宗交易
博济医药：为客户提供流感治疗临床研究服务
证券之星 · 11-25
博济医药：为客户提供流感治疗临床研究服务
博济医药（300404）披露日常经营合同进展公告，11月18日股价下跌1.51%
证券之星 · 11-18
博济医药（300404）披露日常经营合同进展公告，11月18日股价下跌1.51%
博济医药（300404）披露子公司获得药物临床试验批准通知书，11月11日股价上涨0.39%
证券之星 · 11-11
博济医药（300404）披露子公司获得药物临床试验批准通知书，11月11日股价上涨0.39%
博济医药(300404.SZ)子公司卿芷软膏获得药物临床试验批准通知书
智通财经 · 11-11
博济医药(300404.SZ)子公司卿芷软膏获得药物临床试验批准通知书
博济医药（300404）2025年三季报简析：增收不增利，公司应收账款体量较大
中金财经 · 10-30
博济医药（300404）2025年三季报简析：增收不增利，公司应收账款体量较大
图解博济医药三季报：第三季度单季净利润同比下降51.73%
证券之星 · 10-28
图解博济医药三季报：第三季度单季净利润同比下降51.73%
博济医药：持续发展临床前药学研究和药物评价业务
证券之星 · 10-28
博济医药：持续发展临床前药学研究和药物评价业务
博济医药（300404）披露子公司获得药品注册证书，10月23日股价下跌0.3%
证券之星 · 10-23
博济医药（300404）披露子公司获得药品注册证书，10月23日股价下跌0.3%
博济医药最新公告：子公司获得复方聚乙二醇电解质散（Ⅲ）药品注册证书
证券之星 · 10-23
博济医药最新公告：子公司获得复方聚乙二醇电解质散（Ⅲ）药品注册证书
10月17日博济医药发布公告，股东减持116.1万股
证券之星 · 10-17
10月17日博济医药发布公告，股东减持116.1万股
小方制药(603207.SH)委托博济医药技术开发中药1.1类新药“复方侧柏酊”(脱发适应症)
智通财经 · 09-25
小方制药(603207.SH)委托博济医药技术开发中药1.1类新药“复方侧柏酊”(脱发适应症)
博济医药最新公告：公司获得一种测定鞣酸小檗碱中没食子酸的方法的发明专利
证券之星 · 09-19
博济医药最新公告：公司获得一种测定鞣酸小檗碱中没食子酸的方法的发明专利
博济医药：控股股东减持计划出于个人资金需求
证券之星 · 09-16
博济医药：控股股东减持计划出于个人资金需求
博济医药（300404）发布2025年第一次临时股东大会决议公告，9月12日股价上涨1.21%
证券之星 · 09-12
博济医药（300404）发布2025年第一次临时股东大会决议公告，9月12日股价上涨1.21%
博济医药(300404.SZ)：“FCZR”获得药物临床试验批准通知书
智通财经 · 09-03
博济医药(300404.SZ)：“FCZR”获得药物临床试验批准通知书
博济医药（300404）2025年中报简析：增收不增利，公司应收账款体量较大
证券之星 · 08-28
博济医药（300404）2025年中报简析：增收不增利，公司应收账款体量较大
股市必读：博济医药中报 - 第二季度单季净利润同比下降14.34%
证券之星 · 08-28
股市必读：博济医药中报 - 第二季度单季净利润同比下降14.34%
加载更多
公司概况
公司名称：
博济医药科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2015-04-24
主营业务：
博济医药科技股份有限公司的主营业务是为国内外制药企业及其他研究机构就新药品、医疗器械的研发与生产提供全流程“一站式”CRO服务。公司的主要产品是临床研究服务、临床前研究服务、临床前自主研发、其他咨询服务。作为国内领先的CRO公司，公司在报告期内荣膺“2024中国医药CRO企业20强（排名第8）”“2024年度中国医药研发50强”“中国生命科学服务企业百强”卓越成就奖等荣誉称号。
发行价格：
12.87
{"stockData":{"symbol":"300404","market":"SZ","secType":"STK","nameCN":"博济医药","latestPrice":9.64,"timestamp":1764918234000,"preClose":9.57,"halted":0,"volume":6007619,"delay":0,"changeRate":0.0073,"floatShares":281000000,"shares":386000000,"eps":0.0193,"marketStatus":"已收盘","change":0.07,"latestTime":"12-05 15:00:00","open":9.57,"high":9.66,"low":9.45,"amount":57552600,"amplitude":0.0219,"askPrice":9.64,"askSize":326,"bidPrice":9.63,"bidSize":145,"shortable":0,"etf":0,"ttmEps":0.0193,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":5,"adr":0,"adjPreClose":9.57,"symbolType":"stock","openAndCloseTimeList":[[1764898200000,1764905400000],[1764910800000,1764918000000]],"highLimit":10.53,"lowLimit":8.61,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":385727998,"isCdr":false,"pbRate":3.62,"roa":"--","peRate":499.481865,"roe":"2.21%","epsLYR":0.0753,"committee":0.102865,"marketValue":3718000000,"turnoverRate":0.0214,"status":0,"floatMarketCap":2707000000},"requestUrl":"/m/hq/s/300404","defaultTab":"news","newsList":[{"id":"2588884762","title":"博济医药：12月3日高管王廷春减持股份合计240.91万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588884762","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588884762?lang=zh_cn&edition=full","pubTime":"2025-12-04 21:02","pubTimestamp":1764853332,"startTime":"0","endTime":"0","summary":"证券之星消息，根据12月4日市场公开信息、上市公司公告及交易所披露数据整理，博济医药（300404）最新董监高及相关人员股份变动情况：2025年12月3日公司董事,高管王廷春共减持公司股份240.91万股，占公司总股本为0.6246%。变动期间公司股价下跌1.81%，12月3日当日收盘报9.74元。博济医药近半年内的董监高及核心技术人员增减持详情如下：博济医药的高管列表及最新持股情况如下：该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400037359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"gpt_icon":0},{"id":"2588537460","title":"博济医药：12月1日高管王廷春减持股份合计48万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588537460","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588537460?lang=zh_cn&edition=full","pubTime":"2025-12-02 21:03","pubTimestamp":1764680599,"startTime":"0","endTime":"0","summary":"证券之星消息，根据12月2日市场公开信息、上市公司公告及交易所披露数据整理，博济医药（300404）最新董监高及相关人员股份变动情况：2025年12月1日公司董事,高管王廷春共减持公司股份48.0万股，占公司总股本为0.1244%。变动期间公司股价下跌0.7%，12月1日当日收盘报9.94元。博济医药近半年内的董监高及核心技术人员增减持详情如下：博济医药的高管列表及最新持股情况如下：该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200037340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"gpt_icon":0},{"id":"2588725881","title":"12月1日博济医药现690.4万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2588725881","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588725881?lang=zh_cn&edition=full","pubTime":"2025-12-01 17:42","pubTimestamp":1764582143,"startTime":"0","endTime":"0","summary":"证券之星消息，12月1日博济医药发生大宗交易，交易数据如下：近三个月该股共发生2笔大宗交易，合计成交7300.0手，折价成交2笔。该股在过去半年内已有共计23.0万股限售解禁股上市，占公司总股本的0.06%。截至2025年12月1日收盘，博济医药(300404)报收于9.94元，下跌0.7%，换手率2.97%，成交量8.33万手，成交额8308.38万元。该股近半年内有股东持股变动，合计净减持116.1万股，股东增减持明细如下表：该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100022414.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"gpt_icon":0},{"id":"2586473871","title":"博济医药：为客户提供流感治疗临床研究服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2586473871","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586473871?lang=zh_cn&edition=full","pubTime":"2025-11-25 20:52","pubTimestamp":1764075175,"startTime":"0","endTime":"0","summary":"证券之星消息，博济医药(300404)11月24日在投资者关系平台上答复投资者关心的问题。投资者提问：现在流感盛行，请问贵公司有利用AI制药研发生产甲流或者其他流感新药吗？谢谢！博济医药回复：您好，目前公司暂未自主研发相关药物，但有为客户提供多个针对不同受试人群的治疗甲型流感、普通流感及其他急性上呼吸道感染的临床前、临床研究服务，并积极借助AI技术提高效率和质量。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500036314.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"gpt_icon":0},{"id":"2584955963","title":"博济医药（300404）披露日常经营合同进展公告，11月18日股价下跌1.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584955963","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584955963?lang=zh_cn&edition=full","pubTime":"2025-11-18 22:31","pubTimestamp":1763476286,"startTime":"0","endTime":"0","summary":"截至2025年11月18日收盘，博济医药报收于10.45元，较前一交易日下跌1.51%，最新总市值为40.31亿元。该股当日开盘10.53元，最高10.7元，最低10.38元，成交额达1.34亿元，换手率为4.52%。本次补充协议无需董事会审议，不构成关联交易和重大资产重组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800040065.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"gpt_icon":0},{"id":"2582670583","title":"博济医药（300404）披露子公司获得药物临床试验批准通知书，11月11日股价上涨0.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582670583","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582670583?lang=zh_cn&edition=full","pubTime":"2025-11-11 22:40","pubTimestamp":1762872034,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘，博济医药报收于10.18元，较前一交易日上涨0.39%，最新总市值为39.27亿元。该股当日开盘10.14元，最高10.22元，最低10.05元，成交额达1.02亿元，换手率为3.58%。公司近日发布公告称，其全资子公司广州博济新药临床研究中心有限公司申报的“卿芷软膏”已获得国家药品监督管理局签发的《药物临床试验批准通知书》，同意该药品开展用于膝骨关节炎的临床试验。公告显示，卿芷软膏为中药1.1类创新药，适应症为膝骨关节炎风寒湿痹证。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100041157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"gpt_icon":0},{"id":"2582555753","title":"博济医药(300404.SZ)子公司卿芷软膏获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2582555753","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582555753?lang=zh_cn&edition=full","pubTime":"2025-11-11 15:47","pubTimestamp":1762847233,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博济医药(300404.SZ)发布公告，近日，公司全资子公司广州博济新药临床研究中心有限公司申报的“卿芷软膏”获得国家药品监督管理局核准签发的《药物临床试验批准通知书》。“卿芷软膏”为多味饮片在中医药理论指导下组方而成的制剂，属于未在境内外上市的中药新处方制剂，为1.1类中药创新药。本药品用于膝骨关节炎风寒湿痹证，主治祛风胜湿，散寒通络，行气止痛。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367717.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","300404"],"gpt_icon":0},{"id":"2579156277","title":"博济医药（300404）2025年三季报简析：增收不增利，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2579156277","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579156277?lang=zh_cn&edition=full","pubTime":"2025-10-30 08:06","pubTimestamp":1761782765,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期博济医药发布2025年三季报。截至本报告期末，公司营业总收入5.84亿元，同比上升5.07%，归母净利润2191.39万元，同比下降49.36%。本报告期博济医药公司应收账款体量较大，当期应收账款占最新年报归母净利润比达679.65%。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202510/30/20251030396683.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202510/30/20251030396683.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251030/31748836.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300404","BK0216"],"gpt_icon":0},{"id":"2578930471","title":"图解博济医药三季报：第三季度单季净利润同比下降51.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578930471","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578930471?lang=zh_cn&edition=full","pubTime":"2025-10-28 18:54","pubTimestamp":1761648847,"startTime":"0","endTime":"0","summary":"证券之星消息，博济医药2025年三季报显示，公司主营收入5.84亿元，同比上升5.07%；归母净利润2191.39万元，同比下降49.36%；扣非净利润1498.12万元，同比下降57.06%；其中2025年第三季度，公司单季度主营收入2.23亿元，同比上升3.78%；单季度归母净利润634.4万元，同比下降51.73%；单季度扣非净利润299.29万元，同比下降67.57%；负债率33.62%，投资收益42.26万元，财务费用98.03万元，毛利率28.83%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800035238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404"],"gpt_icon":0},{"id":"2578660658","title":"博济医药：持续发展临床前药学研究和药物评价业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2578660658","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578660658?lang=zh_cn&edition=full","pubTime":"2025-10-28 09:01","pubTimestamp":1761613272,"startTime":"0","endTime":"0","summary":"投资者提问：建议公司增加药物研发投入，增强公司在临床前cro服务商中的地位与市场占有率，早日跻身top10。公司是一家专业的CRO服务提供商，以临床试验服务为主，近几年公司营收也持续增长，未来在保持临床试验服务优势的前提下，持续发展临床前药学研究和药物评价业务并持续加强自主创新能力，稳步开发自主研发品种，着手推进主营业务链条的医药合同定制研发生产服务，充分发挥“一站式”全流程服务的优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800009832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"gpt_icon":0},{"id":"2577855925","title":"博济医药（300404）披露子公司获得药品注册证书，10月23日股价下跌0.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577855925","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577855925?lang=zh_cn&edition=full","pubTime":"2025-10-23 22:38","pubTimestamp":1761230292,"startTime":"0","endTime":"0","summary":"截至2025年10月23日收盘，博济医药报收于9.92元，较前一交易日下跌0.3%，最新总市值为38.26亿元。公司近日发布公告称，其全资子公司广州华圣制药有限公司申报的“复方聚乙二醇电解质散（Ⅲ）”已获得国家药品监督管理局核准签发的《药品注册证书》。药品注册分类为化学药品4类，上市许可持有人为广州华圣制药有限公司，药品批准文号为国药准字H20255557，有效期至2030年09月22日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102300037996.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"gpt_icon":0},{"id":"2577377036","title":"博济医药最新公告：子公司获得复方聚乙二醇电解质散（Ⅲ）药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2577377036","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577377036?lang=zh_cn&edition=full","pubTime":"2025-10-23 18:10","pubTimestamp":1761214258,"startTime":"0","endTime":"0","summary":"博济医药(300404.SZ)公告称，公司全资子公司广州华圣制药有限公司申报的“复方聚乙二醇电解质散（Ⅲ）”获得国家药品监督管理局核准签发的《药品注册证书》。该药品适用于内窥镜或放射检查、结肠手术前的成年人患者结肠清洁准备，已在中国城市和县级公立医院的销售规模约为2.2亿元。此次获得《药品注册证书》不会对公司经营业绩产生重大影响，公司将根据药品后续进展情况履行信息披露义务。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102300030446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"gpt_icon":0},{"id":"2576031562","title":"10月17日博济医药发布公告，股东减持116.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2576031562","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576031562?lang=zh_cn&edition=full","pubTime":"2025-10-17 19:01","pubTimestamp":1760698892,"startTime":"0","endTime":"0","summary":"证券之星消息，10月17日博济医药发布公告《博济医药:关于控股股东及其一致行动人减持股份进展暨权益变动触及1%的公告》，其股东横琴广金美好基金管理有限公司-广金美好费米十三号私募证券投资基金于2025年9月12日至2025年10月17日间合计减持116.1万股，占公司目前总股本的0.3011%，变动期间该股股价下跌9.58%，截止10月17日收盘报9.72元。股东增减持详情见下表：根据博济医药2025年中报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101700031709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"gpt_icon":0},{"id":"2570061090","title":"小方制药(603207.SH)委托博济医药技术开发中药1.1类新药“复方侧柏酊”(脱发适应症)","url":"https://stock-news.laohu8.com/highlight/detail?id=2570061090","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570061090?lang=zh_cn&edition=full","pubTime":"2025-09-25 16:13","pubTimestamp":1758787987,"startTime":"0","endTime":"0","summary":"智通财经APP讯，小方制药(603207.SH)发布公告，公司近日与博济医药科技股份有限公司(简称“博济医药”)签署了《技术委托(开发)合同》，博济医药将协助公司完成中药 1.1 类复方侧柏酊新药临床研究及注册，推动其完成临床试验及上市。本次公司与博济医药签署的《技术委托(开发)合同》，是双方基于共同发展战略的一次强强联合，标志着公司在创新药领域布局迈出重要一步。博济医药作为行业领先企业，在研发实力、技术积累和临床资源方面具有显著优势，双方合作将充分发挥各自专长，形成协同效应，有效提升合同产品的研发效率与成功率，为产品后续申报及上市奠定坚实基础。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1349327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300404","603207","BK0239","BK0216"],"gpt_icon":0},{"id":"2568256006","title":"博济医药最新公告：公司获得一种测定鞣酸小檗碱中没食子酸的方法的发明专利","url":"https://stock-news.laohu8.com/highlight/detail?id=2568256006","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568256006?lang=zh_cn&edition=full","pubTime":"2025-09-19 17:10","pubTimestamp":1758273041,"startTime":"0","endTime":"0","summary":"博济医药(300404.SZ)公告称，公司近日获得国家知识产权局颁发的一项发明专利证书，该专利涉及药品成分检测领域，提供了一种测定鞣酸小檗碱中没食子酸的方法。该方法实现了鞣酸小檗碱中鞣酸、小檗碱和没食子酸的良好分离，检测时间短，分离度高。该专利的获得对公司经营业绩不会产生重大影响，但有利于公司的技术创新，完善知识产权保护体系，提升公司核心竞争力。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091900025633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"gpt_icon":0},{"id":"2567009541","title":"博济医药：控股股东减持计划出于个人资金需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2567009541","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567009541?lang=zh_cn&edition=full","pubTime":"2025-09-16 20:52","pubTimestamp":1758027125,"startTime":"0","endTime":"0","summary":"证券之星消息，博济医药(300404)09月15日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司9月12—12月11日的减持计划是因为个人什么资金需求？还是不看好公司了呢。博济医药回复：您好，公司控股股东的减持计划是出于其个人资金的需求，希望投资者能够理性看待。公司管理层对公司长期发展充满信心，对公司的经营和发展从未松懈。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091600035849.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"gpt_icon":0},{"id":"2566836970","title":"博济医药（300404）发布2025年第一次临时股东大会决议公告，9月12日股价上涨1.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2566836970","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566836970?lang=zh_cn&edition=full","pubTime":"2025-09-12 22:32","pubTimestamp":1757687570,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘，博济医药报收于10.88元，较前一交易日上涨1.21%，最新总市值为41.95亿元。该股当日开盘10.74元，最高10.94元，最低10.56元，成交额达2.14亿元，换手率为7.1%。2025年9月13日，公司发布《2025年第一次临时股东大会决议公告》。公告显示，博济医药科技股份有限公司于2025年9月12日召开2025年第一次临时股东大会，会议采用现场与网络投票相结合方式，审议通过了12项议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091200038561.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"gpt_icon":0},{"id":"2564136870","title":"博济医药(300404.SZ)：“FCZR”获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2564136870","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564136870?lang=zh_cn&edition=full","pubTime":"2025-09-03 15:57","pubTimestamp":1756886271,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博济医药(300404.SZ)发布公告，近日，公司申报的“FCZR”获得国家药品监督管理局核准签发的《药物临床试验批准通知书》。FCZR是在已知活性成分的基础上，对其剂型、处方工艺、给药途径、适应症等进行优化，且具有明显临床优势的2.2/2.4类改良型新药，拟定适应症为耳真菌病。耳真菌病是耳鼻咽喉科门诊较常见的一类感染性疾病，高温潮湿的季节和地区多见，常反复发作、不易根治。FCZR剂型具有流动性和给药操作便利上的优势，滴耳给药可直接与耳道内各隐蔽角落的病灶接触，发挥局部给药局部起效的作用。目前国内外尚无该类药品获批上市，亦无相关销售数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1340975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300404","BK0216"],"gpt_icon":0},{"id":"2562594776","title":"博济医药（300404）2025年中报简析：增收不增利，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2562594776","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562594776?lang=zh_cn&edition=full","pubTime":"2025-08-28 06:28","pubTimestamp":1756333689,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期博济医药发布2025年中报。本报告期博济医药公司应收账款体量较大，当期应收账款占最新年报归母净利润比达565.35%。目前市场临床 CRO业务需求有所暖，2025年上半年公司商务部门参与竞标的临床项目较去年同期明显增长，公司也在持续扩充临床业务团队人员。2025年下半年公司将根据业务情况新增临床业务人员，预计整体人员会继续增加，但不会大规模扩张。2025年全年公司的目标营收以 2024年限制性股票激励计划目标为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082800006428.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"gpt_icon":0},{"id":"2562724013","title":"股市必读：博济医药中报 - 第二季度单季净利润同比下降14.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562724013","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562724013?lang=zh_cn&edition=full","pubTime":"2025-08-28 03:09","pubTimestamp":1756321784,"startTime":"0","endTime":"0","summary":"业绩披露要点博济医药2025年中报显示，公司主营收入3.61亿元，同比上升5.88%；归母净利润1556.99万元，同比下降48.33%；扣非净利润1198.83万元，同比下降53.28%。其中2025年第二季度，公司单季度主营收入2.23亿元，同比上升27.95%；单季度归母净利润1166.93万元，同比下降14.34%；单季度扣非净利润1029.04万元，同比下降7.85%；负债率33.89%，投资收益30.12万元，财务费用66.86万元，毛利率30.65%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082800002584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765028608434,"stockEarnings":[{"period":"1week","weight":-0.037},{"period":"1month","weight":-0.0455},{"period":"3month","weight":-0.1091},{"period":"6month","weight":0.0906},{"period":"1year","weight":0.0525},{"period":"ytd","weight":0.1055}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0167},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.1529},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1644}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"博济医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"29555人(较上一季度增加18.91%)","perCapita":"9500股","listingDate":"2015-04-24","address":"广东省广州市黄埔区科学城南翔一路62号(二、三、四、五)栋","registeredCapital":"38572万元","survey":" 博济医药科技股份有限公司的主营业务是为国内外制药企业及其他研究机构就新药品、医疗器械的研发与生产提供全流程“一站式”CRO服务。公司的主要产品是临床研究服务、临床前研究服务、临床前自主研发、其他咨询服务。作为国内领先的CRO公司，公司在报告期内荣膺“2024中国医药CRO企业20强（排名第8）”“2024年度中国医药研发50强”“中国生命科学服务企业百强”卓越成就奖等荣誉称号。","listedPrice":12.87},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博济医药(300404)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博济医药(300404)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博济医药,300404,博济医药股票,博济医药股票老虎,博济医药股票老虎国际,博济医药行情,博济医药股票行情,博济医药股价,博济医药股市,博济医药股票价格,博济医药股票交易,博济医药股票购买,博济医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博济医药(300404)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博济医药(300404)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}